From Promise to Peril: The Downfall of Ginkgo Bioworks - Ginkgo Bioworks Holdings ( NYSE:DNA )
In a report released in October 2021, Scorpion Capital alleged Ginkgo Bioworks Holdings Inc of being a "colossal scam", claiming that the company, at a $23 billion valuation, was ridiculously overpriced.
| Ticker |
Sentiment |
Impact |
|
MSFT
|
Somewhat Bullish
|
3 %
|
|
DNA
|
Neutral
|
21 %
|
